

CEO name- Mr. Ran Yam \* Select a CATEGORY: Biotech/Pharma Health IT/Digital Select one SESSION per abstract from the list below \* “Restoring Vision: Where Biology Meets Engineering.”

- Executive Summary / Investment Rational: Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths. TrackSight is an AI eye-tracking software for myopia control, digitizing myopic blur and contrast reduction on everyday screens. It addresses the global myopia market with an accessible, scalable model. Early studies showed significant axial-length shortening; a 150-child multicenter trial is underway in Israel and Hong Kong. Following a \$5M round, NovaSight plans to add additional vision wellness features.
- Core Technology: What is the technology, its uniqueness, and its value proposition? TrackSight is a patented AI eye-tracking soft for myopia control that runs on standard tablets and laptops. It uniquely digitizes myopic blur and contrast reduction, applying real-time, gaze-contingent peripheral chromatic blur while preserving a clear central view. Its value proposition is scalable, accessible, usertransparent myopia management on everyday screens, as a standalone or adjunctive solution.
- Product Profile/Pipeline: Briefly describe the company’s product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships. NovaSight’s pipeline includes commercial of CureSight, eye tracking based lazy eye treatment and TrackSight, a myopia prevention and monitoring software in clinical development. TrackSight has shown promising early axial-length results, with a 150-child multicenter trial underway in Israel and Hong Kong. Its large global myopia market supports strong potential, with key milestones in clinical validation, regulatory progress, and collaborations with strategic partners.
- Business Strategy: Briefly describe how the company will apply its core technology, generate short-term and long-term revenues. NovaSight developments in vision case uses eye-tracking technology, both infra-red through the FDAcleared and CE-marked CureSight device, while TrackSight, currently in clinical trials, with AI-based eye tracking through the embedded camera on consumer devices. Short-term, revenues are generated based on the utilization of CureSight in the U.S., EU, and Asia. In the long term, additional revenues are expected to be generated from TrackSight commercialization, global growth, and future digital visionwellness offerings.
- What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans Next, NovaSight plans to complete TrackSight’s 150-child multicenter randomized trial in Israel and Hong Kong, expand R&D with vision-wellness features, prepare for commercialization, and support growth through business-model refinement, international expansion, and financing that could position TrackSight as a strategic M&A enabler.